From: Benefits and harms of medical cannabis: a scoping review of systematic reviews
Author, year {refid} | Search dates; # databases searched | Funding source | Nstudies | Illness/condition | Intervention/comparator* | Outcomes | Conclusions from data | AMSTAR-2 rating |
---|---|---|---|---|---|---|---|---|
Huntley, 2000 [66] | Inception to Dec 1999; 4 | NR | 1 | Asthma | I: Plant-derived cannabinoids C: Placebo | • Airway resistance (raw) | Only one study included | M |
Singh, 2007 [77] | Inception to Dec 2004; 6 | Non-profit | 4 | Asthma | I: Plant-based cannabis C: Placebo; isoproterenol; low-dose marijuana | • Pulmonary function test | Reported SBS | M |
Snedecor, 2013 [70] | To Jun 2011; 5 | Industry | 1 | Diabetes | I: Plant-derived cannabinoids C: placebo | • Peripheral NP (mean reduction in pain) • Peripheral NP (mean probability of 30% pain reduction) | Unclear efficacy (not enough information provided by authors) | L |
Norton, 2017 [28] | Inception–Feb 2016; 5 | NR | 3 | Inflammatory bowel disease | I: Plant-based cannabis C: No comparator (observational study) | N/A observational data | N/A observational data | CL |
Langhorst, 2015 [44] | Inception–Mar 12, 2014; 4 | Non-profit | 1 | Inflammatory bowel disease (Crohn's, ulcerative colitis, IBS) | I: Plant-based cannabis C: Placebo cigarettes (THC removed) | • Response rate • QoL • Remission rate | Only one study included | M |
CADTH, 2014 [81] | Jan 1, 1982 to Aug 8 2014; 5 | NR | 4 | Nausea and vomiting (non-chemotherapy-induced) | I: Synthetic cannabinoids C: Metoclopramide | • Postoperative nausea and vomiting • Patient rating of nausea and vomiting (VAS) | Only one study included | L |